Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 蘇尼替尼是一種新型的多靶點酪氨酸激酶抑製劑。
Electively targeting of signaling pathways using protein kinase inhibitors would have a potential advantage over receptor blockers. 這種用來選擇性地阻斷信號轉導途徑的蛋白激酶抑製劑可能是一種潛在的有利的受體阻斷劑。
滬公網安備 31011502000490號
電信業務許可證編號：滬B2-20190700
